Keros Therapeutics (NASDAQ:KROS) Price Target Raised to $111.00

Keros Therapeutics (NASDAQ:KROS) had its price target boosted by research analysts at Wells Fargo & Company from $88.00 to $111.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price would indicate a potential upside of 65.08% from the company’s current price.

KROS has been the subject of several other research reports. HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of Keros Therapeutics in a research report on Thursday, November 7th. Guggenheim reiterated a “buy” rating and set a $102.00 target price (up previously from $96.00) on shares of Keros Therapeutics in a research note on Wednesday, December 4th. Scotiabank began coverage on shares of Keros Therapeutics in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Keros Therapeutics in a report on Friday, November 22nd. Finally, Bank of America dropped their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research note on Thursday, September 12th. Twelve analysts have rated the stock with a buy rating, Based on data from MarketBeat, Keros Therapeutics currently has an average rating of “Buy” and an average target price of $95.22.

Keros Therapeutics Stock Up 1.4 %

Shares of NASDAQ KROS traded up $0.93 on Wednesday, hitting $67.24. The company had a trading volume of 19,113 shares, compared to its average volume of 376,474. The business has a 50 day moving average of $60.63 and a two-hundred day moving average of $52.96. The firm has a market capitalization of $2.72 billion, a P/E ratio of -12.91 and a beta of 1.20. Keros Therapeutics has a 12-month low of $27.31 and a 12-month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. Keros Therapeutics’s quarterly revenue was up 4750.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.33) EPS. On average, sell-side analysts anticipate that Keros Therapeutics will post -5.26 earnings per share for the current year.

Institutional Trading of Keros Therapeutics

Several hedge funds have recently added to or reduced their stakes in KROS. KBC Group NV raised its stake in shares of Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after buying an additional 280 shares during the period. Values First Advisors Inc. bought a new stake in shares of Keros Therapeutics during the 3rd quarter worth about $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Keros Therapeutics in the 2nd quarter worth approximately $128,000. Finally, LMR Partners LLP bought a new position in shares of Keros Therapeutics in the third quarter valued at approximately $213,000. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.